Comparison · NCT02930018-sae
Nerinetide, 2.6 mg/kg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nerinetide, 2.6 mg/kg vs Placebo: serious adverse events. Trial comparisons, record NCT02930018-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02930018-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.331 | 0.293 | 0.371 | wilson | |
| Risk in group 2 | 0.357 | 0.319 | 0.398 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0265 | -0.0823 | 0.0296 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.926 | 0.786 | 1.09 | log | |
| Odds ratio, group 1 over group 2 | 0.889 | 0.693 | 1.14 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Nerinetide, 2.6 mg/kg than on Placebo | 37.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nerinetide, 2.6 mg/kg | Single intravenous infusion of nerinetide over 10 ± 1 minutes | 181 | 547 | EG001 |
| Group 2 | Placebo | Drug vehicle only~Placebo: Placebo Comparator: Placebo | 198 | 554 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse Events occurring within 30 days of randomization and all Serious Adverse Events up to the end of study visit (Day 90 visit or death) or until the subject was deemed lost to follow-up were reported.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke
- NCT number
- NCT02930018
- Phases
- PHASE3
- Conditions
- Stroke, Acute
- Interventions
- Nerinetide (NA-1), 2.6 mg/kg, Placebo
- Lead sponsor
- NoNO Inc.
- Results first posted
- 2020-12-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02930018?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02930018-sae